RTP Mobile Logo
Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Hepatobiliary Cancers (Webinar Video Proceedings)
Released February 2022

Featuring perspectives from Prof Ghassan Abou-Alfa, Dr Richard Finn and Dr Robin Kelley, moderated by Dr Tanios Bekaii-Saab. Published February 21, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hepatobiliary cancers.

    LEARNING OBJECTIVES

    • Consider patient age, performance status, liver function and other clinical and logistical factors in the selection of first- and later-line therapy for unresectable or metastatic hepatocellular carcinoma (HCC).
    • Consider the FDA approval of olaparib as maintenance therapy for patients with metastatic pancreatic adenocarcinoma (PAD) with deleterious or suspected deleterious germline BRCA mutations and without disease progression on a first-line platinum-based chemotherapy regimen.
    • Apply clinical trial data with approved and investigational systemic interventions for patients with localized, locally advanced or metastatic PAD to establish an evidence-based approach to selecting therapy.
    • Appraise available and emerging data with investigational agents currently in clinical testing for HCC, PAD, and biliary tract cancers, and appropriately refer eligible patients for clinical trial participation.
    • Evaluate the data with approved and investigational agents targeting FGFR2 fusions or rearrangements in patients with cholangiocarcinoma, and identify individuals who would benefit from this strategy.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOGI22/HCC/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY & MODERATOR — The following faculty and moderator reported relevant financial relationships with ineligible entities:

    FACULTY

    Ghassan Abou-Alfa, MD, MBA
    Professor
    Attending Physician
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Consulting Agreements: Adicet Bio, Alnylam Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Autem Medical, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Berry Genomics, Celgene Corporation, Cend Therapeutics Inc, CytomX Therapeutics, Eisai Inc, Exelixis Inc, Flatiron Health, Genentech, a member of the Roche Group, Genoscience Pharma, Helio Health, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Legend Biotech, Lilly, Merck, Nerviano Medical Sciences Srl, QED Therapeutics, Rafael Pharmaceuticals Inc, RedHill Biopharma Ltd, Servier Pharmaceuticals LLC, Silenseed Ltd, Sobi, Surface Oncology, TheraBionic, Vector Pharma, Yiviva; Contracted Research: Agios Pharmaceuticals Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BioNTech, Bristol-Myers Squibb Company, Celgene Corporation, Flatiron Health, Genentech, a member of the Roche Group, Genoscience Pharma, Incyte Corporation, Polaris Pharmaceuticals, Puma Biotechnology Inc, QED Therapeutics, Silenseed Ltd, Yiviva.

    Richard S Finn, MD
    Professor, Department of Medicine, Division of Hematology/Oncology
    David Geffen School of Medicine at UCLA
    Director, Signal Transduction and Therapeutics Program
    Jonsson Comprehensive Cancer Center at UCLA
    Los Angeles, California

    Advisory Committee: CStone Pharmaceuticals; Consulting Agreements: Adaptimmune, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, CStone Pharmaceuticals, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Lilly, Merck, Pfizer Inc; Contracted Research (to UCLA): Adaptimmune, Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech, a member of the Roche Group, Lilly, Merck, Pfizer Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Hengrui Therapeutics Inc.

    Robin K (Katie) Kelley, MD
    Associate Professor of Clinical Medicine
    Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco (UCSF)
    San Francisco, California

    Advisory Committee: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Merck; Consulting Agreement: Exact Sciences Inc; Contracted Research: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Lilly, Merck, Novartis, Partner Therapeutics, QED Therapeutics, Surface Oncology, Taiho Oncology Inc; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group, Merck.

    MODERATOR

    Tanios Bekaii-Saab, MD
    Professor, Mayo Clinic College of Medicine and Science
    Program Leader, Gastrointestinal Cancer
    Mayo Clinic Cancer Center
    Consultant, Mayo Clinic in Arizona
    Chair, ACCRU Research Consortium
    Phoenix, Arizona

    Advisory Committee: Immuneering Corporation, Imugene, Sun Biopharma; Consulting Agreements (to Institution): Arcus Biosciences, Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Pfizer Inc, Seagen Inc; Consulting Agreements (to Self): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Celularity, Daiichi Sankyo Inc, Eisai Inc, Exact Sciences, Foundation Medicine, Janssen Biotech Inc, Kanaph Therapeutics, Natera Inc, Sobi, Stemline Therapeutics Inc, Treos Bio, Xilis; Research Funding (to Institution): AbGenomics, Agios Pharmaceuticals Inc, Amgen Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Atreca, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Merus BV, Mirati Therapeutics, Novartis, Pfizer Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc; Data and Safety Monitoring Board/Committee: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Exelixis Inc, FibroGen, Kintor, Lilly, Pancreatic Cancer Action Network; Inventions/Patents: WO/2018/183488, WO/2019/055687.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Exelixis Inc, Genentech, a member of the Roche Group, Incyte Corporation and Zymeworks Inc.

    Release date: February 2022
    Expiration date: February 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):